Equine Viral Arteritis

Equine Typhoid, Epizootic Cellulitis–Pinkeye, Epizootic Lymphangitis Pinkeye, Rotlaufseuche

Last Updated: December 2022



The Center for Food Security & Public Health



INSTITUTE FOR INTERNATIONAL COOPERATION IN ANIMAL BIOLOGICS

IOWA STATE UNIVERSITY College of Veterinary Medicine



World Organisation for Animal Health Founded as OIE



Importance

Equine viral arteritis is an economically important viral disease of equids. Stallions can transmit this virus during breeding and sometimes become long-term virus carriers in semen. Although carrier stallions can be bred if precautions are taken, the need to mate them with seropositive or vaccinated mares decreases their desirability as breeders. Acute illnesses are also seen occasionally, though many infections in nonpregnant animals are subclinical. While deaths are very rare in healthy adults, pregnant mares that become infected may abort, and very young foals may die of fulminant pneumonia and enteritis. Some reports suggest that equine viral arteritis may be increasing in prevalence due to the increased transportation of horses and semen.

Etiology

Equine viral arteritis is caused by equine arteritis virus (EAV; official species name *Alphaarterivirus equid*), an RNA virus in the genus *Alphaarterivirus*, family Arteriviridae and order Nidovirales. Only one serotype is recognized; however, there are a number of antigenic variants, and some isolates of EAV are more virulent than others. There are two known viral lineages, North American and European, and several clades within these lineages. EAV strains that differed significantly from either lineage were reported in some donkeys in South Africa, and other divergent strains may also exist, particularly as there is only limited information about the viruses circulating in Africa, Asia or the Middle East.

Species Affected

Equine arteritis virus infects equids. Clinical cases have been reported mainly in horses and ponies; however, antibodies to EAV are also found in donkeys and zebras, and experimentally infected donkeys developed clinical signs. EAV might also be able to cause disease in South American camelids, as a PCR test detected viral nucleic acids in an alpaca that had aborted; however, this remains to be confirmed by further studies and virus isolation.

Zoonotic potential

There is no indication that EAV can infect humans.

Geographic Distribution

Serological and/or virological evidence for the presence of EAV has been found in North and South America, Europe, Asia, Africa and Australia, as well as in most individual countries where testing has been done. However, this virus is reported to be absent from a few locations including Iceland and Japan. New Zealand appears to have successfully eliminated EAV circulation in horses, and the general population of equids there was reported to be virus-free in 2013.

The North American and European lineages are not limited to the continents where they originated, and can occur in other locations.

Transmission

Acutely affected horses excrete EAV in respiratory secretions, and this virus can be transmitted in aerosols where susceptible horses are in close contact. It has also been found in other secretions and excretions, including urine and feces, and occurs in the reproductive tracts of mares (vaginal and uterine secretions, ovary, oviduct) and stallions (semen). Venereal transmission is common, with stallions spreading the virus via both artificial insemination and natural service. Semen remains infectious after freezing. EAV was also shown to be transmissible via embryo transfer if the donor mare was inseminated with infected semen. Mares infected late in pregnancy may give birth to infected foals.

Mares, geldings and sexually immature colts eliminate EAV completely after an infection; however, stallions can continue to carry the virus subclinically in the male reproductive tract and shed it in semen for periods ranging from weeks to years. Some of these carriers eventually clear the infection, but others remain infected for life.

Equine Viral Arteritis

EAV can occasionally be found for up to six months in the reproductive tract of older prepubertal colts, but they do not become true carriers.

EAV can be transmitted on fomites (e.g., equipment) and mechanical vectors such as humans or animals. Under some conditions, this virus can withstand heat of 37-38°C (99-100°F) for 2-3 days, or cold of 4-8°C (39-46°F) for up to 75 days; however, it is sensitive to sunlight and low humidity.

Disinfection

EAV is readily destroyed by detergents, common disinfectants (e.g., sodium hypochlorite, iodides and quaternary ammonium compounds) and lipid solvents such as ether or chloroform. It is inactivated in 20–30 minutes at 56-58°C (133-136°F).

Incubation Period

The incubation period ranges from 2 days to 2 weeks. Infections transmitted venereally tend to become apparent in about a week.

Clinical Signs

Equine viral arteritis is generally more severe in old or very young animals, and in horses that are immunocompromised or in poor condition. Most infections, including those that occur in mares bred to long-term carriers, are subclinical.

Fulminant infections with severe interstitial pneumonia and/ or enteritis can be seen in foals up to a few months of age, including some congenitally infected newborns. Adult horses occasionally develop a systemic illness, with clinical signs that often include varying degrees of fever, depression, anorexia, rhinitis, and dependent edema of the prepuce, scrotum, mammary gland, ventral body wall and/ or limbs, particularly the hindlegs. Some horses may also have conjunctivitis, photophobia, periorbital or supraorbital edema, urticaria and petechiae on the mucous membranes. Urticaria may be localized to the head and/or neck or generalized. Pregnant mares may abort or give birth to a stillborn foal, with or without any other clinical signs. Stallions may experience a temporary decrease in fertility, with reduced quality sperm and decreased libido, during the acute stage of the disease. The decrease in sperm quality has been attributed to increased scrotal temperature and edema, and can persist for up to 4 months. The quality of the semen is not decreased in carrier stallions. Except in cases of severe disease in foals, deaths are rare.

Outbreaks have not been reported among donkeys or mules, and although antibodies have been found, there is relatively little information about the clinical signs in these species. Fever, sometimes accompanied by mild depression, mild conjunctivitis, slight oculonasal discharge and/or mild dependent edema, was reported in donkeys inoculated with an EAV strain that is moderately virulent for horses. These signs were mild enough that they could readily have been missed if the animals were not closely monitored. Donkeys inoculated with a South African donkey strain had similar clinical signs; however, while some cases were mild, others were more severe. Pregnant donkeys did not abort in this study, and their foals were clinically normal when born. Horses inoculated with the South African donkey strain developed only very mild signs.

Post Mortem Lesions

Acutely ill animals may have edema, congestion and hemorrhages in the subcutaneous tissues, particularly those of the limbs and abdomen, and in various visceral organs and lymph nodes. The thoracic and abdominal lymph nodes, and the small and large intestines (especially the colon and cecum) are frequently affected, and the peritoneal cavity, pleura and pericardium may contain clear, yellowish fluid. Severely affected young foals often have pulmonary edema, interstitial pneumonia, emphysema, splenic infarcts and/or enteritis.

Aborted fetuses tend to be partially autolyzed, though they are sometimes well preserved. The only gross lesions in some fetuses may be excess fluid in the body cavities and signs of interlobular interstitial pneumonia. The endometrium of mares that aborted may be swollen and congested, and sometimes contains hemorrhagic lesions.

Diagnostic Tests

Equine viral arteritis can be diagnosed by virus isolation, the detection of viral nucleic acids or antigens, and serology.

Culture and/or RT-PCR may detect EAV in nasopharyngeal swabs or washings, conjunctival swabs, blood and semen from recently infected animals, as well as in a number of tissues at necropsy. The placenta, fetal fluids and fetal tissues (particularly lymphoid tissues, lung and spleen) are generally sampled in aborted fetuses or stillborn foals, while organs and lymph nodes associated with the respiratory and gastrointestinal tracts (e.g., lungs, liver, spleen) are collected in young foals that died of a systemic illness. In live animals, samples for virus detection, other than semen, should be collected as soon as possible after the onset of clinical signs. Blood samples intended for virus isolation should use acid citrate dextrose or EDTA as an anticoagulant, as heparin may inhibit the growth of RK-13cells, the most commonly used cell line. The identity of the recovered virus can be confirmed by serum neutralization, RT-PCR, immunofluorescence or immunohistochemistry. An antigen-capture ELISA for use with culture supernatants has also been described.

Immunohistochemistry may identify viral antigens in tissue samples, including some taken from organs with no apparent lesions. It has also been used to identify acutely infected horses from skin biopsies, though this was not completely reliable. Histopathology is helpful in clinical cases, particularly abortions. Tissues likely to contain typical histopathological changes include the cecum, colon, spleen and associated lymph nodes, and adrenal cortex.

Carrier stallions can be identified by virus isolation or RT-PCR on semen. Samples should contain the sperm-rich fraction of the ejaculate, as EAV is not found in the presperm fraction. Carriers can also be detected by breeding the stallion to two seronegative mares, which are checked for seroconversion 4 weeks after breeding. Secretions and excretions other than semen do not contain EAV in carriers.

In recently infected horses, serology should demonstrate a fourfold increase in titer in paired acute and convalescent samples. Virus neutralization (e.g., the complement enhanced microneutralization test) and ELISAs are the most commonly used tests, but other assays such as complement fixation, the fluorescent microsphere immunoassay (MIA), agar gel immunodiffusion and indirect fluorescent antibody may also be available.

Treatment

Treatment is supportive, and most healthy horses recover on their own. Although some antivirals appear promising against EAV *in vitro*, there are no reports of their use in live animals.

Control

Disease reporting

Veterinarians who encounter or suspect equine viral arteritis should follow their national and/or local guidelines for disease reporting. State regulations should be consulted in the U.S., where this disease is reportable in many states.

Prevention

Isolating infected horses during an outbreak may reduce transmission. Precautions should also be taken to avoid spreading the virus on fomites. Equine viral arteritis vaccines appear to reduce virus shedding, in addition to preventing clinical signs, and may help contain outbreaks. However, live attenuated vaccines may cause some abortions in pregnant mares (probably mainly or exclusively during the last 2-3 months of gestation) and they are not recommended for any pregnant animals unless a high risk of abortion from EAV exposure outweighs this consideration. Live attenuated vaccines are also not recommended for young foals < 6 months of age, or the dams of these foals.

Venereal transmission and abortions can be controlled by good management and vaccination. Newly acquired horses should be isolated for 3-4 weeks, and pregnant mares should be separated from other horses and maintained in small groups according to their predicted foaling dates. To prevent venereal transmission, stallions should be tested for EAV, and carrier stallions should only be bred to well vaccinated or naturally seropositive mares. Because firsttime vaccinates may shed the virus for a short time after being bred to a carrier, these mares should be isolated from seronegative horses, particularly pregnant mares, for 3 weeks. Naturally infected mares and those that are not firsttime vaccinates are isolated for 24-48 hours. Excellent hygiene and decontamination of fomites should be practiced when breeding infected horses or collecting semen.

Live attenuated vaccines appear to prevent uninfected stallions from becoming long-term carriers, and stallions are regularly vaccinated before the start of the breeding season in some counties. Prepubertal colts are given the

Equine Viral Arteritis

vaccine when they are 6-12 months old. The efficacy of killed vaccines in preventing carriage is not as well characterized. Although uninfected stallions have been kept near carriers for years without becoming infected, in one case the virus was apparently transmitted by indirect exposure to semen, and it has been recommended that carrier stallions be housed where they can be physically separated from uninfected horses. While there is no proven method to eliminate carriage in stallions, initial studies of anti-GnRH vaccines seem to be promising. One or more doses of a vaccine appeared to clear the virus from the semen of 15 carriers within 1-2 years, though it also caused persistent deficits in reproductive function in a minority of these animals.

New Zealand used annual testing, the identification of carrier stallions and control of transmission from these animals, and selective vaccination to eradicate equine viral arteritis.

Morbidity and Mortality

The prevalence of EAV in horses varies, and it is known to be higher in some breeds than others. Particularly high exposure rates, with approximately 25-70% or higher seroprevalence in unvaccinated individuals, have been reported in Standardbreds in the U.S., Warmbloods in Europe and Hucul horses in Poland, among others. In contrast, antibodies were found in less than 5% of unvaccinated Warmbloods in the U.S. Persistent carriage in stallions is likely to influence virus prevalence, and has ranged from < 10% to 70% in different outbreaks. Whether a stallion has a susceptible or resistant phenotype in the EqCXCL16 gene has been shown to strongly influence whether or not it becomes a long-term carrier.

EAV infections are frequently inapparent, and clinical outbreaks are uncommon. In many cases, outbreaks have been associated with horses being moved or semen shipped. The clinical signs caused by most field strains are often mild, though they may be more severe in old or very young animals, and in horses that are immunocompromised or in poor condition. Reported abortion rates in outbreaks have ranged from < 10% to \geq 50%. Deaths primarily occur in very young foals, and are very rare in healthy adults. While immunity to EAV is though to be long-lasting, some horses can become reinfected.

Internet Resources

Food and Agriculture Organization of the United Nations (FAO). Manual for the Recognition of Exotic Diseases of Livestock

The Merck Veterinary Manual

<u>United States Department of Agriculture (USDA) Animal</u> and Plant Health Inspection Service (APHIS). Equine viral arteritis

World Organization for Animal Health (WOAH)

Equine Viral Arteritis

WOAH Manual of Diagnostic Tests and Vaccines for Terrestrial Animals

WOAH Terrestrial Animal Health Code

Acknowledgements

This factsheet was written by Anna Rovid Spickler, DVM, PhD, Veterinary Specialist from the Center for Food Security and Public Health. The U.S. Department of Agriculture Animal and Plant Health Inspection Service (USDA APHIS) provided funding for this factsheet through a series of cooperative agreements related to the development of resources for initial accreditation training.

The following format can be used to cite this factsheet. Spickler, Anna Rovid. 2022. Equine Viral Arteritis. Retrieved from <u>http://www.cfsph.iastate.edu/DiseaseInfo/</u><u>factsheets.php</u>.

References

- Amat JP, Vergne T, Tapprest J, Ferry B, Hans A, Hendrikx P, Dufour B,. Leblond A. Estimating the incidence of equine viral arteritis and the sensitivity of its surveillance in the French breeding stock. Vet Microbiol. 2016;30(192):34-42.
- Animal Health Australia. The National Animal Health Information System [NAHIS] Equine viral arteritis [online]. Available at: http://www.aahc.com.au/nahis/disease/dislist.asp.* Accessed 3 Oct 2001.
- Balasuriya UB, Go YY, MacLachlan NJ. Equine arteritis virus. Vet Microbiol. 2013;167(1-2):93-122.
- Balasuriya UB, Carossino M. Reproductive effects of arteriviruses: equine arteritis virus and porcine reproductive and respiratory syndrome virus infections. Curr Opin Virol. 2017;27:57-70.
- Balasuriya UB, Sarkar S, Carossino M, Go YY, Chelvarajan, L, Cook RF, Loynachan AT, Timoney PJ, Bailey E. Host factors that contribute to equine arteritis virus persistence in the stallion: an update. J Eq Vet Sci. 2016;43:S11-S17.
- Borchers K, Wiik H, Frölich K, Ludwig H, East ML. Antibodies against equine herpesviruses and equine arteritis virus in Burchell's zebras (*Equus burchelli*) from the Serengeti ecosystem. J Wildl Dis. 2005;41(1):80-6.
- BroaddusCC. Balasuriya UBR, White JLR, Timoney PJ, Funk RA, Holyoak GR. Evaluation of the safety of vaccinating mares against equine viral arteritis during mid or late gestation or during the immediate postpartum period. JAVMA. 2011;238(6) 741-50.
- Campbell ML. Equine viral arteritis. Vet Rec. 2006;158(13):455.
- Campos JR, Breheny P, Araujo RR, Troedsson MHT, Squires EL, Timoney PJ, Balasuriya UBR. Semen quality of stallions challenged with the Kentucky 84 strain of equine arteritis virus. Theriogenology. 2014;82(8):1068-79.
- Del Piero F. Equine viral arteritis. Vet Pathol. 2000;37(4):287-96.
- Gilkerson JR, Bailey KE, Diaz-Méndez A, Hartley CA. Update on viral diseases of the equine respiratory tract. Vet Clin North Am Equine Pract. 2015 Apr;31(1):91-104.

- Go YY, Bailey E, Cook FR, Coleman SJ, Macleod JN, Chen KC, Timoney PJ, Balasuriya UB. Genome-wide association study among four horse breeds identifies a common haplotype associated with *in vitro* CD3+ T cell susceptibility/resistance to equine arteritis virus infection. J Virol. 2011;85:13174-84.
- Go YY, Bailey E, Timoney PJ, Shuck KM, Balasuriya UB. Evidence that *in vitro* susceptibility of CD3+ T lymphocytes to equine arteritis virus infection reflects genetic predisposition of naturally infected stallions to become carriers of the virus. J Virol. 2012;86(22):12407-10.
- Go YY, Cook RF, Fulgencio JQ, Campos JR, Henney P, Timoney PJ, Horohov DW, Balasuriya UB. Assessment of correlation between *in vitro* CD3(+) T cell susceptibility to EAV infection and clinical outcome following experimental infection. Vet. Microbiol. 2012;157(1-2):220-5.
- Holyoak GR, Balasuriya UB, Broaddus CC, Timoney PJ. Equine viral arteritis: current status and prevention. Theriogenology. 2008;70(3):403-14.
- Horner GW. Equine viral arteritis control scheme: a brief review with emphasis on laboratory aspects of the scheme in New Zealand. N Z Vet J. 2004;52(2):82-4.
- McCollum WH, Timoney PJ, Tengelsen LA. Clinical, virological and serological responses of donkeys to intranasal inoculation with the KY-84 strain of equine arteritis virus. J Comp Pathol. 1995;112(2):207-11.
- McFadden AMJ, Pearce PV, Orr D, Nicoll K, Rawdon TG, Pharo H, Stone M. Evidence for absence of equine arteritis virus in the horse population of New Zealand. New Zealand Vet J. 2013;61(5):300-4.
- MiszczAk F, Burger D, Ferry B, LeGrand L, Fortier G, Laine A-L, Vabret A, Pronost S, Vidament M. Anti-GnRH vaccination of stallions shedding equine arteritis virus in their semen: a field study. Vet Arhiv. 2020;90:543-56.
- Paweska JT. Effect of the South African asinine-94 strain of equine arteritis virus (EAV) in pregnant donkey mares and duration of maternal immunity in foals. Onderstepoort J Vet Res. 1997;64(2):147-52.
- Paweska JT, Aitchison H, Chirnside ED, Barnard BJ. Transmission of the South African asinine strain of equine arteritis virus (EAV) among horses and between donkeys and horses. Onderstepoort J Vet Res. 1996;63(3):189-96.
- Qi TH, Hu Y, Hu Z, Zhao S, Cullinane A, Lyons P, Gildea S, Wang X. Development of an antigen-capture ELISA for the quantitation of equine arteritis virus in culture supernatant. Arch Virol. 2018;163(6): 1469-78.
- Sarkar S, Bailey E, Go YY, Cook RF, Kalbfleisch T, Eberth J, Chelvarajan RL, Shuck KM, Artiushin S, Timoney PJ, Balasuriya UBR. Allelic variation in CXCL16 determines CD3+ T lymphocyte susceptibility to equine arteritis virus infection and establishment of long-term carrier state in the stallion. PLoS Genet.2016;12: e1006467.
- Shirai J. Kanno T, Tsuchiya Y, Mitsubayashi S, Seki R. Effects of chlorine, iodine, and quaternary ammonium compound disinfectants on several exotic disease viruses. J Vet Med Sci. 2000;62(1):85-92.
- Stadejek T, Mittelholzer Ch, Oleksiewicz MB, Paweska J, Belák S. Highly diverse type of equine arteritis virus (EAV) from the semen of a South African donkey: short communication. Acta Vet Hung. 2006;54(2):263-70.

Equine Viral Arteritis

- Steinbach F, Westcott DG, McGowan SL, Grierson SS, Frossard JP, Choudhury B. Re-emergence of a genetic outlier strain of equine arteritis virus: Impact on phylogeny. Virus Res. 2015;202:144-50.
- Timoney PJ. Equine viral arteritis. In: Winter AL, Moses MA, editors. The Merck veterinary manual. Rathway, NJ: Merck and Co; 2022. Available at: <u>https://www.merckvetmanual.com/generalized-</u> <u>conditions/equine-viral-arteritis/equine-viral-arteritis.</u> Accessed 2 Dec 2022.
- United States Department of Agriculture. Animal and Plant Health Inspection Service [USDA APHIS]. Equine viral arteritis (EVA) and the U.S. horse industry #N315.0400 [online]. USDA APHIS; 2000 April. Available at: http://www.aphis.usda.gov:80/vs/ceah/cahm/Equine/eq98eva. htm.* Accessed 26 Sept. 2001.
- Vairo S, Saey V, Bombardi C, Ducatelle R, Nauwynck H. The recent European isolate (08P178) of equine arteritis virus causes inflammation but not arteritis in experimentally infected ponies. J Comparative Pathol. 2014;151:238-43.
- World Organization for Animal Health (OIE). World animal health information database (WAHID) [database online]. Equine viral arteritis. Paris:OIE;2009. Available at: http://www.oie.int/wahis/public.php?page=disease_status_lists.* Accessed 20 Jun 2009.
- World Organization for Animal Health (OIE). Manual of diagnostic tests and vaccines for terrestrial animals [online].
 Paris: OIE; 2013. Equine viral arteritis. Available at: <u>https://www.woah.org/fileadmin/Home/eng/Health_standards/ tahm/3.06.10_EVA.pdf</u>. Accessed 1 Dec 2022.

*Link defunct